Hepatitis C Victims Present Petition With 10,000 Signatures Urging Nihon Pharma To Apologize
This article was originally published in PharmAsia News
Executive Summary
Roughly 20 plaintiffs and lawyers representing hepatitis C victims met with three executives of Tokyo-based Nihon Pharma, one of three pharmaceutical companies sued in the case, and urged the company to take responsibility and apologize to the victims. The group delivered a petition with 10,000 signatures and demanded a reply this January. (Click here for more-Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.